Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas

By sjmartinez • October 15, 2023

Attia S, Villalobos V, Hindi N, Wagner AJ, Chmielowski B, Oakley GJ 3rd, Peterson PM, Ceccarelli M, Jones RL, Dickson MA. Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers (Basel). 2023 Oct 6;15(19):4871. doi: 10.3390/cancers15194871. PMID: 37835565; PMCID: PMC10572019.

Tags: docetaxel, gemcitabine, Hematology/Oncology, leiomyosarcoma, olaratumab, overall survival, Progression-free survival, Publications, soft tissue sarcomas

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi[...]

Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance

Markosian C, Buckley CW, Chai-Ho W, Schiller GJ. Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance. Leuk[...]

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

Su Y, Liu C, Lu X, Chuang HY, Li G, Shao S, Kong Y, Lee JW, Ng RH, Wong S, Robert L, Warden C, Liu[...]